Form 4 for DXCM Dexcom
Accepted 2023-05-22 00:00:00 ET · period of report 2023-05-18 · accession 0001093557-23-000136 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-22 | 2023-05-18 | DXCM | Malady Kyle | Dir | A - Grant | $0.00 | +2,885 | 15.5K | +23% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-18 | A | A | 2,885 | $0.00 | 15,529 | D | — | — | (F1) The RSU Award was granted on May 18, 2023 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2024 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. (F2) Included in this number are 4,581 unvested restricted stock units, 2,885 of which were granted on May 18, 2023 and shall vest on the earlier of the one year anniversary of the grant or the date of DexCom Inc's 2024 Annual Meeting and 1,696 of which were granted on October 11, 2020 and shall vest through October 11, 2023. |